The global polyarticular juvenile idiopathic arthritis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Idiopathic arthritis is defined as a group of disorders that causes arthritis (stiff, swollen, painful joints) in children. It is an autoimmune disease. During the first 6 months of illness, children with polyarticular juvenile idiopathic arthritis have arthritis in five or more joints. According to American College of Rheumatology (ACR) a child must have inflammation in one or more joints lasting at least 6 weeks, be under 16 years old and have all other conditions ruled out before being diagnosed with juvenile idiopathic arthritis. 

The standard of care entails taking methotrexate first, although many physicians start with a biologic or the disease-modifying antirheumatic drug (DMARD) combination to combat inflammation as quickly as possible. As doctors monitor the disease, drugs may be added or removed. DMARD drugs work by modifying the course of the disease and even relieve symptoms by suppressing the immune system so it does not attack the joints. These have been used the longest and have a broad immune-suppressing effect. The most commonly-used drug for juvenile idiopathic arthritis is methotrexate available in pill as well as injection form. 

However, biologics drugs target certain steps or chemicals in the inflammatory process and may work more quickly than traditional DMARDs. They are self-injected or given by infusion in a doctor’s office. Drugs that relieve the symptoms of polyarticular juvenile idiopathic arthritis include the nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics (pain relievers). These drugs relieve pain, However, cannot reduce joint damage or change the course of juvenile idiopathic arthritis. These medications are available over-the-counter or by prescription. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type 

o By Route of Administration

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  F. Hoffman La-Roche AG, AbbVie Inc., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Report by Segment

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

• Disease Modifying Anti-Rheumatic Drugs (DMARDs)

• Biologic Agents

• Corticosteroids

• Others

By Route of Administration

• Oral

• Injectable

Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa